Thromboresistant and endothelialization effects of dopamine-mediated heparin coating on a stent material surface

Journal of Materials Science: Materials in Medicine

Volumn 23, Issue 5, 2012, Pages 1259-1269

  Bae, In Ho ^a,b   Park, In Kyu ^a   Park, Dae Sung ^a   Lee, Haeshin ^c   Jeong, Myung Ho ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Korea Cardiovascular Stent Research Institute   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIVE PROTEINS; ANTI-PROLIFERATIVE; CYTOTOXICITY ASSAYS; ENDOTHELIALIZATION; HEPARINIZATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; IN-VITRO; IN-VIVO; MATERIAL SURFACE; RESTENOSIS RATES; STABLE STATE; SURFACE STABILITY; THROMBUS FORMATION; TOLUIDINE BLUE;

ANIMALS; ASSAYS; BIOCOMPATIBILITY; CHROMIUM; COATINGS; COBALT; ENDOTHELIAL CELLS; NEUROPHYSIOLOGY; POLYSACCHARIDES; SURFACE PROPERTIES;

STENTS;

CHROMIUM; COBALT; DOPAMINE; HEPARIN; THROMBIN; TOLONIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIALIZATION; ENDOTHELIUM; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STENT; SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DOPAMINE; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; THROMBOSIS;

ANIMALIA;

EID: 84863332192     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-012-4587-5     Document Type: Article

References (59)

1. Dibra A, Kastrati A, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J, Schomig A. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:616-23. (Pubitemid 46177448)
2. Scott NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev. 2006;58: 358-76. (Pubitemid 43816739)
3. Tung R, Kaul S, Diamond GA, Shah PK. Narrative review: drugeluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med. 2006;144:913-9. (Pubitemid 46768132)
4. Leon MB. Late thrombosis a concern with drug-eluting stents. J Interv Cardiol. 2007;20:26-9. (Pubitemid 46161061)
5. Ong AT, Serruys PW. Technology Insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med. 2005;2:647-58. (Pubitemid 43012602)
6. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769-76. (Pubitemid 35315761)
7. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002;41:391-412.
8. Vrolix MC, Legrand VM, Reiber JH, Grollier G, Schalij MJ, Brunel P, Martinez-Elbal L, Gomez-Recio M, Bar FW, Bertrand ME, Colombo A, Brachman J. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol. 2000;86:385-9. (Pubitemid 30628602)
9. Kim YJ, Kang IK, Huh MW, Yoon SC. Surface characterization and in vitro blood compatibility of poly(ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge. Biomaterials. 2000;21:121-30.
10. Chen H, Chen Y, Sheardown H, Brook MA. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials. 2005;26:7418-24. (Pubitemid 41133593)
11. Liu Q, Ding J, Mante FK, Wunder SL, Baran GR. The role of surface functional groups in calcium phosphate nucleation on titanium foil: a self-assembled monolayer technique. Biomaterials. 2002;23:3103-11. (Pubitemid 34522123)
12. Fu J, Ji J, Yuan W, Shen J. Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials. 2005;26:6684-92. (Pubitemid 41021761)
13. Meng S, Liu Z, Shen L, Guo Z, Chou LL, Zhong W, Du Q, Ge J. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials. 2009;30:2276-83.
14. Lee H, Dellatore SM, Miller WM, Messersmith PB. Musselinspired surface chemistry for multifunctional coatings. Science. 2007;318:426-30. (Pubitemid 47614522)
15. Rich DH. SingJ. In: Gross E, Meinenhofer J, editors. The peptides. New York: Academic Press; 1982. p. 243-63.
16. You I, Kang S, Byun Y, Lee H. Enhancement of blood compatibility of poly(urethane) Substrates by Mussel-inspired adhesive heparin coating. Bioconjug Chem. 2011;22:1264-9.
17. Gilles MA, Hudson AQ, Borders CL Jr. Stability of water-soluble carbodiimides in aqueous solution. Anal Biochem. 1990;184: 244-8. (Pubitemid 20055618)
18. Jee KS, Park HD, Park KD, Kim YH, Shin JW. Heparin conjugated polylactide as a blood compatible material. Biomacromolecules. 2004;5:1877-81. (Pubitemid 39335228)
19. Hinrichs W, Hoopen H, Wissink M, Engbers G, Feijen J. Design of a new type of coating for the controlled release of heparin. J Control Rel. 1997;45:163-76. (Pubitemid 27065218)
20. Chen JL, Li LQ, Chen JY, Chen C, Huang N. Improving bloodcompatibility of titanium by coating collagen-heparin multilayers. Appl Surf Sci. 2009;255:6894-900.
21. Poussard L, Burel F, Couvercelle JP, Merhi Y, Tabrizian M, Bunel C. Hemocompatibilty of new ionic polyurethanes: influence of carboxylic group insertion modes. Biomaterials. 2004;25: 3473-83. (Pubitemid 38327036)
22. Rodrigues SN, Goncalves IC, Martins MC, Barbosa MA, Ratner BD. Fibrinogen adsorption, platelet adhesion and activation on mixed hydroxyl-/methyl- terminated self-assembled monolayers. Biomaterials. 2006;27:5357-67. (Pubitemid 44093714)
23. Chandler WL, Solomon DD, Hu CB, Schmer G. Estimation of surface-bound heparin activity: a comparison of methods. J Biomed Mater Res. 1988;22:497-508.
24. Yang W, Ge J, Liu H, Zhao K, Liu X, Qu X, Li W, Huang Y, Sun A, Zou Y. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model. Cardiovasc Res. 2006;72: 483-93. (Pubitemid 44665846)
25. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv. 2008;1:143-53.
26. Hou C, Yuan Q, Huo D, Zheng S, Zhan D. Investigation on clotting and hemolysis characteristics of heparin-immobilized polyether sulfones biomembrane. J Biomed Mater Res A. 2008;85:847-52. (Pubitemid 351632898)
27. Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization and in vitro evaluation. Biomaterials. 2001;22:151-63.
28. Waite JH. Reverse engineering of bioadhesion in marine mussels. Ann N Y Acad Sci. 1999;875:301-9. (Pubitemid 29349081)
29. Papov VV, Diamond TV, Biemann K, Waite JH. Hydroxyargininecontaining polyphenolic proteins in the adhesive plaques of the marine mussel Mytilus edulis. J Biol Chem. 1995;270:20183-92.
30. Waite JH, Qin X. Polyphosphoprotein from the adhesive pads of Mytilus edulis. Biochemistry. 2001;40:2887-93. (Pubitemid 32198291)
31. Harrington MJ, Masic A, Holten-Andersen N, Waite JH, Fratzl P. Iron-clad fibers: a metal-based biological strategy for hard flexible coatings. Science. 2010;328:216-20.
32. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus MN. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A. 2004;71:625-34. (Pubitemid 39578676)
33. Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirschinger J, Schomig A. Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized doubleblind controlled trial. Catheter Cardiovasc Interv. 2005;65:374-80. (Pubitemid 40898181)
34. Lin Q, Yan J, Qiu F, Song X, Fu G, Ji J. Heparin/collagen multilayer as a thromboresistant and endothelial favorable coating for intravascular stent. J Biomed Mater Res A. 2011;96:132-41.
35. Shin YM, Lee YB, Shin H. Time-dependent mussel-inspired functionalization of poly(l-lactide-co-varepsilon-caprolactone) substrates for tunable cell behaviors. Colloids Surf B Biointerfaces. 2011;87:79-87.
36. Nunes GL, Thomas CN, Hanson SR, Barry JJ, King SB III, Scott NA. Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon. Circulation. 1995;92: 1697-700.
37. Shim D, Wechsler DS, Lloyd TR, Beekman RH III. Hemolysis following coil embolization of a patent ductus arteriosus. Catheter Cardiovasc Diagn. 1996;39:287-90. (Pubitemid 26383006)
38. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs. 1983;11:161-73. (Pubitemid 14168691)
39. Park KD, Okano T, Nojiri C, Kim SW. Heparin immobilization onto segmented polyurethane-urea surfaces: effect of hydrophilic spacers. J Biomed Mater Res. 1988;22:977-92.
40. Senatore F, Shankar H, Chen JH, Avantsa S, Feola M, Posteraro R, Blackwell E. In vitro and in vivo studies of heparinized-collageno- elastic tubes. J Biomed Mater Res. 1990;24:939-57. (Pubitemid 20319156)
41. Kashiwagi T, Ito Y, Imanishi Y. Non-thrombogenicity of organic polymers by blending with alkylamine-heparin complexes. Biomaterials. 1993;14:1145-53. (Pubitemid 24061572)
42. Erdtmann M, Keller R, Baumann H. Photochemical immobilization of heparin, dermatan sulphate, dextran sulphate and endothelial cell surface heparan sulphate onto cellulose membranes for the preparation of athrombogenic and antithrombogenic polymers. Biomaterials. 1994;15:1043-8.
43. Hansi C, Arab A, Rzany A, Ahrens I, Bode C, Hehrlein C. Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. Catheter Cardiovasc Interv. 2009;73:488-96.
44. Ren Y, Yang K, Zhang B. In vitro study of platelet adhesion on medical nickel-free stainless steel surface. Mater Lett. 2005;59: 1785-9. (Pubitemid 40509573)
45. Li L, Tu M, Mou S, Zhou C. Preparation and blood compatibility of polysiloxane/liquid-crystal composite membranes. Biomaterials. 2001;22:2595-9. (Pubitemid 32727833)
46. te Velthuis H, Baufreton C, Jansen PG, Thijs CM, Hack CE, Sturk A, Wildevuur CR, Loisance DY. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg. 1997;114:117-22. (Pubitemid 27315305)
47. Vogler EA, Graper JC, Harper GR, Sugg HW, Lander LM, Brittain WJ. Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res. 1995;29:1005-16.
48. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-93. (Pubitemid 32830406)
49. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-9. (Pubitemid 32678280)
50. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89: 133-8. (Pubitemid 36115090)
51. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsil L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus- eluting stent: should we be cautious? Circulation. 2004;109:701-5. (Pubitemid 38222887)
52. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drugeluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
53. Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am Heart J. 2006;152: 1168-74. (Pubitemid 44854799)
54. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373-85. (Pubitemid 39303937)
55. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, Liew CC, Pratt RE, Dzau VJ. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation. 2004;109:1769-75. (Pubitemid 38500680)
56. Werner N, Nickenig G. Clinical and therapeutical implications of EPC biology in atherosclerosis. J Cell Mol Med. 2006;10:318-32. (Pubitemid 44870182)
57. Popat KC, Leoni L, Grimes CA, Desai TA. Influence of engineered titania nanotubular surfaces on bone cells. Biomaterials. 2007;28:3188-97. (Pubitemid 46654214)
58. Bos GW, Scharenborg NM, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Proliferation of endothelial cells on surface- immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor. J Biomed Mater Res. 1999;44:330-40. (Pubitemid 29019035)
59. Li G, Yang P, Qin W, Maitz MF, Zhou S, Huang N. The effect of coimmobilizing heparin and fibronectin on titanium on hemocompatibility and endothelialization. Biomaterials. 2011;32: 4691-703.